Alkeus Pharmaceuticals Announces New Positive Interim TEASE-3 Study Results Showing Gildeuretinol Prevented Disease Progression in Early-Stage Stargardt Patients Two additional TEASE-3 participants who recently completed 24 months of therapy showed no disease progression, consistent with prior results. A total of five patients have completed the 24-month...

Curevo Vaccine to present at the 43rd Annual J.P. Morgan Healthcare Conference Curevo Vaccine will present at the 2025 JPM Healthcare Conference on Wednesday January 15th.

Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a leading public health company that delivers protective and life-saving solutions to communities across the...

Alkeus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference Alkeus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14.

Inaugural Pre-JPM Partnering Week to Wrap Up 2024, Prepare for 2025 New life science partnering conference to debut that prepares and helps industry dealmakers and stakeholders for the JP Morgan Healthcare Conference week